Abstract
This paper reviews the development of cancer imaging with radiolabeled antibodies to carcinoembryonic antigen and the current status and challenges for cancer therapy with radiolabeled antibodies. Advances in antibody preparations, choice of isotope and labeling methods, as well as imaging methods have resulted in rapid and sensitive radioimmunodetection agents that can affect the management of cancer patients. Radioimmunotherapy faces other problems, but advances in antibody engineering and control of dose-limiting myelotoxicity may result in reproducible clinical responses similar to the encouraging results being obtained in the radioimmunotherapy of lymphomas.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
